Spero Therapeutics, a clinical-stage biopharmaceutical company, will announce its financial results for the first quarter ending March 31, 2026, on May 13 after market close. The company will also provide a business update but will not hold a conference call. This report follows their recent activities including the resubmission of a New Drug Application for tebipenem HBr to the FDA. Investors should watch for insights on the company's progress in developing treatments for rare and high-need diseases.
Temenos has been recognized by CNBC as one of the World’s Top Fintech Companies for the third consecutive year, selected from 3,500 global firms. This accolade reflects Temenos' strong performance and innovation in banking technology, particularly in...
During week 30 of 2026 (July 20-24), Sampo Oyj bought back a total of 1,352,794 of its A-shares at a weighted average price of €9.60 per share. This share buyback is part of a program authorized by the company's general meeting on April 22, 2026, wit...
Bitcoin briefly dropped as U.S. spot bitcoin ETFs saw $465 million in outflows over two days, ending a week-long inflow streak. Despite this, Bitcoin held steady between $63,700 and $65,500, supported by rising U.S. liquidity hitting $5.92 trillion, ...
Rokmaster Resources has entered an exclusive option agreement to acquire 100% interest in the Cristal Property, a 9 km² copper exploration site in northern Chile known for promising geophysical anomalies indicating a potential large porphyry copper s...
AstraZeneca reported second-quarter earnings that surpassed analyst expectations, with core earnings per share rising 21% to $2.63, though revenue slightly missed forecasts at $15.4 billion. Growth in oncology and rare diseases offset weaker sales fr...
